Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2020-018
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Notice of Approval for Drug Clinical Trials
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Jianfeng Yien Biotechnology Co., Ltd. (hereinafter referred to as "Jianfeng Yien") , , a holding subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, "JFAN-1001 Capsule, Notice No: 2020LP00246 " and "JFAN-1001 Capsules, Notification No: 2020LP00247 ". The relevant details are hereby announced as follows:
2. drug basic information content
drug name: JFAN-1001 capsule
English name: JFAN-1001Capsule
dosage form: capsule
application item: clinical research application
specification: 10mg , 30mg
registration classification: chemical drugs category
applicant: Zhejiang Jianfeng yien biotechnology co., ltd
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, 2020 6 February 7 accepted JFAN-1001 glue capsule meets the relevant requirements of drug registration and agrees to carry out clinical trials according to the submitted plan."
3. Drug Research and Development and Registration
JFAN-1001 is a new anti-tumor drug developed by Jianfeng Yien. The registration classification belongs to chemical drug 1 . Jianfeng Yien first submitted JFAN-1001 clinical trial application and was accepted on 2020 6 January 7 (acceptance numbers: CXHL2000255 , CXHL2000256 ). JFAN-1001 is a small molecule antineoplastic agent with indications for EGFR-T790M secondary mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about 4676.04 .03 million yuan.
Market Situation of Similar Drugs in 4.
Currently, targeted drugs for epidermal growth factor receptor (EGFR ) inhibitors listed in China include: the first generation EGFR inhibitors include gefitinib, erlotinib and icotinib; The second generation EGFR inhibitors include afatinib and dacotinib; the third generation EGFR inhibitor includes AstraZeneca's osimertinib, which was approved for listing in the United States on November 11, 2009, , , , and approved for listing in China on March 122, , 2017, . AstraZeneca global annual sales of osimertinib in 2019, , .7 billion (source: 2019# AstraZeneca Annual Financial Statement for 129), almetinib of Jiangsu Haosen Pharmaceutical Co., Ltd. was approved to be listed in China in January , March this year. The company's JFAN-1001 is the third generation EGFR inhibitor with the same target as osimertinib, at present, similar drugs in the clinical research stage include efitinib of Shanghai Alex pharmaceutical technology co., ltd., avetinib of Hangzhou essen pharmaceutical research co., ltd., Nanjing shenghe pharmaceutical co., ltd. SH-1028 , Jiangsu osaikang pharmaceutical co., ltd. ASK120067 , Jiangsu runxin biotechnology co., ltd. RX518 and many other enterprises. Approval Procedure for 5. Products to Be Listed Jianfeng Yien will conduct clinical trials according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, production will be declared. Production and marketing can only be carried out after passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors August 19, 2020
More information
City Red Cross thanks spike help "anti-epidemic"
On February 26, Jinhua City Red Cross Party Secretary, Executive Vice President Shi Yiwei and his entourage to visit the peak, the peak in the prevention and control of the new coronary pneumonia epidemic actively contribute to love, brave social responsibility of the great love and kindness to express gratitude. Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and Xiang Chongping, deputy general manager of the group company, had a discussion with Vice President Shi Yiwei and his party. In order to solve the difficult problems for caring enterprises to resume work and production, the Municipal Red Cross Society, based on its own functional positioning and giving full play to its unique advantages, conducted a large feedback and return visit to caring enterprises, and jointly established three Red Cross volunteer service teams, including traditional Chinese medicine service, psychological assistance, and emergency rescue training, to take "eight measures" to help caring enterprises resume work and production. Vice President Shi Yiwei led the backbone of three volunteer service teams to the peak for a return visit, expressing his gratitude for the contribution made by the peak in the prevention and control of the new coronary pneumonia epidemic, and sent a letter of thanks and the "New Coronary Pneumonia Prevention and Control Enterprises Resuming Work and Resuming Production Protection Manual". Chairman Jiang Xiaomeng introduced the industrial layout, production and operation of the peak, focusing on the resumption of work and production of the peak enterprises, and put forward opinions and suggestions on the reduction and exemption of basic electricity charges for enterprises, the support policies for small and medium-sized enterprises, and the payment of "five insurance and one fund. (Reporter Ni Yingzhen)
2020
07-15
Peak 2013 corporate bonds complete principal and interest payments
News from our newspaper On November 20, Zhejiang Jianfeng Group Co., Ltd. successfully completed the payment of principal and interest on 2013 corporate bonds (Phase II) (hereinafter referred to as "13 Jianfeng 02"). At this point, all the corporate bonds approved for issuance in 2013 have been paid. In 2013, with the approval of document No. [2013]595 of China Securities Regulatory Commission, the company was allowed to issue corporate bonds with a face value of no more than 0.6 billion yuan to the public, with a debt rating of AA +. On June 5, 2013, the Company issued the 2013 Corporate Bonds (Phase I) ("13 Peak 01"), which raised $0.3 billion at a coupon rate of 4.90 per cent, 1.55 percentage points lower than the then five-year benchmark interest rate for bank loans. On November 20, 2014, "13 Peak 02" was successfully issued, raising 0.3 billion yuan again at a coupon rate of 5.09, and was listed on the Shanghai Stock Exchange on December 11, 2014. The ability to raise 0.6 billion yuan from the capital market at a lower cost reflects investors' recognition of the company's "cement + pharmaceutical" dual business structure and expectations of the company's good operating performance. On June 5, 2018, the first issue of Jianfeng Group's 2013 corporate bonds was due to complete the payment of principal and interest, and now the second issue of corporate bonds has also successfully completed the payment of principal and interest. In the real economic growth is weak, business operations continue to explode, the company in a short period of time successfully completed two issues of a total of 0.6 billion yuan of corporate bonds principal and interest payment work, fully reflecting the company's good operating results in recent years.
2020
07-31
Company Leaders Attend Jinhua Development Conference
News from our newspaper On November 17, the second 2019 Jinhua Development Conference with the theme of "Insist on high-quality integration into the Yangtze River Delta to build a metropolitan area" opened in Jinhua, Zhejiang. More than a thousand people from the scientific and educational circles, business circles, and overseas Chinese from home and abroad Business people, representatives of "New Golden Chinese" and representatives of outstanding Jinhua students attended the meeting. Group leaders Jiang Xiaomeng, Yu Jianhong and Huang Jinlong attended the relevant activities of the conference. As a representative of the Jinhua business community, Jiang Xiaomeng, chairman of the group company, made a keynote speech at the "Scientist" and "Entrepreneur" Innovation Dialogue of the Development Conference, expressing his views on how Jinhua enterprises can improve their technological competitiveness. As the head of Jinhua local enterprise with a history of more than 60 years, Jiang Xiaomeng has a profound experience in promoting the development of enterprises through science and technology. Combined with the reality of peak scientific and technological innovation, he pointed out in his speech that the improvement of scientific and technological innovation ability is an urgent event for Jinhua small and medium-sized enterprises. Private enterprises cannot achieve high-quality development without the support of scientific and technological forces; with the progress of society, the improvement of people's living standards and the continuous improvement of cultural quality, the demand for products and the pursuit of product quality have also undergone qualitative changes. Only products with scientific and technological connotations can attract consumers. He suggested that the government and relevant institutions should establish an information platform to further understand the scientific and technological support that enterprises need in the transformation, understand what kind of help scientific and technological personnel can provide to enterprises, do a good job in the information docking of scientists and entrepreneurs, further attract investment and wisdom, give full play to the scientific and technological achievements of academicians and experts and the capital advantages of businessmen at home and abroad, and promote Jinhua enterprises to better integrate into Changsan
2020
07-31
Company Leaders Attend Jinhua Development Conference
News from our newspaper On November 17, the second 2019 Jinhua Development Conference with the theme of "Insist on high-quality integration into the Yangtze River Delta to build a metropolitan area" opened in Jinhua, Zhejiang. More than a thousand people from the scientific and educational circles, business circles, and overseas Chinese from home and abroad Business people, representatives of "New Golden Chinese" and representatives of outstanding Jinhua students attended the meeting. Group leaders Jiang Xiaomeng, Yu Jianhong and Huang Jinlong attended the relevant activities of the conference. As a representative of the Jinhua business community, Jiang Xiaomeng, chairman of the group company, made a keynote speech at the "Scientist" and "Entrepreneur" Innovation Dialogue of the Development Conference, expressing his views on how Jinhua enterprises can improve their technological competitiveness. As the head of Jinhua local enterprise with a history of more than 60 years, Jiang Xiaomeng has a profound experience in promoting the development of enterprises through science and technology. Combined with the reality of peak scientific and technological innovation, he pointed out in his speech that the improvement of scientific and technological innovation ability is an urgent event for Jinhua small and medium-sized enterprises. Private enterprises cannot achieve high-quality development without the support of scientific and technological forces; with the progress of society, the improvement of people's living standards and the continuous improvement of cultural quality, the demand for products and the pursuit of product quality have also undergone qualitative changes. Only products with scientific and technological connotations can attract consumers. He suggested that the government and relevant institutions should establish an information platform to further understand the scientific and technological support that enterprises need in the transformation, understand what kind of help scientific and technological personnel can provide to enterprises, do a good job in the information docking of scientists and entrepreneurs, further attract investment and wisdom, give full play to the scientific and technological achievements of academicians and experts and the capital advantages of businessmen at home and abroad, and promote Jinhua enterprises to better integrate into Changsan
2020
07-22
The Party Committee of the Group conducts thematic education and concentrated study.
On November 12, the Party Committee of the Group Company held a "Do not forget your initiative mind, Keeping in mind the mission" thematic education and study meeting to focus on the relevant spirit of the central and higher Party committees on thematic education and the key points in the "Decision of the Central Committee of the Communist Party of China on Adhering to and Improving the Socialist System with Chinese Characteristics, Promoting the Modernization of the National Governance System and Governance Capacity" previously held at the Fourth Plenary Session of the 19th CPC Central Committee of the 19th CPC Central Committee, and make arrangements for further promoting thematic education in the whole group. According to the central government's schedule for the second batch of thematic education, the group party committee requires all party members and cadres to deeply understand the significance of carrying out the thematic education of "not forgetting the original heart and keeping in mind the mission", and firmly grasp the "keep the original heart, undertake the mission, find the gap, and grasp the implementation" The general requirements of the group party committee members will also go to various enterprises separately in the near future, carry out research on the development of theme education, the current difficulties faced by enterprises and the issues of concern to employees, so as to achieve the effect of closely combining theme education with the promotion of enterprise management, and strengthening the close combination of party building and enterprise development. (this newspaper reporter)
2020
07-31
Company Leaders Attend Jinhua Development Conference
News from our newspaper On November 17, the second 2019 Jinhua Development Conference with the theme of "Insist on high-quality integration into the Yangtze River Delta to build a metropolitan area" opened in Jinhua, Zhejiang. More than a thousand people from the scientific and educational circles, business circles, and overseas Chinese from home and abroad Business people, representatives of "New Golden Chinese" and representatives of outstanding Jinhua students attended the meeting. Group leaders Jiang Xiaomeng, Yu Jianhong and Huang Jinlong attended the relevant activities of the conference. As a representative of the Jinhua business community, Jiang Xiaomeng, chairman of the group company, made a keynote speech at the "Scientist" and "Entrepreneur" Innovation Dialogue of the Development Conference, expressing his views on how Jinhua enterprises can improve their technological competitiveness. As the head of Jinhua local enterprise with a history of more than 60 years, Jiang Xiaomeng has a profound experience in promoting the development of enterprises through science and technology. Combined with the reality of peak scientific and technological innovation, he pointed out in his speech that the improvement of scientific and technological innovation ability is an urgent event for Jinhua small and medium-sized enterprises. Private enterprises cannot achieve high-quality development without the support of scientific and technological forces; with the progress of society, the improvement of people's living standards and the continuous improvement of cultural quality, the demand for products and the pursuit of product quality have also undergone qualitative changes. Only products with scientific and technological connotations can attract consumers. He suggested that the government and relevant institutions should establish an information platform to further understand the scientific and technological support that enterprises need in the transformation, understand what kind of help scientific and technological personnel can provide to enterprises, do a good job in the information docking of scientists and entrepreneurs, further attract investment and wisdom, give full play to the scientific and technological achievements of academicians and experts and the capital advantages of businessmen at home and abroad, and promote Jinhua enterprises to better integrate into Changsan
2020
07-31